PHARMENA SA is a publicly traded specialty healthcare company, which develops and markets innovative products based on a patented, physiological and natural active substance Regen7 molecule®. The company has well diversified portfolio covering indications such as: excessive hair loss, dandruff, mid/moderate acne, sunburns, skin allergies and anti-aging. At the same time, we are engaged in the development of new oral medicines for the treatment of cardiovascular diseases and other disorders. More information at: http://www.dermenum.eu/ .

The latest product release of Pharmena SA is a patented dietary supplement product line called Menavitin.

This innovative product is based on 1-MNA active substance and has the ability to influence the risk of cardiovascular diseases on biomarkers and to stimulate the production of endogenous (natural) prostacyclin. Low level of prostacyclin in the body increases the risk of atherosclerosis. The supplement may, therefore, supplement the level of 1-MNA, and thus stimulate the secretion of prostacyclin in particular in the elderly, reducing the risk of atherosclerosis. More information at: https://www.menavitin.pl/en, https://1-mna.eu/